Skip to main content
SpringerLink
Log in

Noncompliance with Antihypertensive Therapy

Economic Consequences

  • Current Opinion
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598–615

    Article  PubMed  CAS  Google Scholar 

  2. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the Second Working Party of the British Hypertension Society. BMJ 1993; 306: 983–7

    Article  PubMed  CAS  Google Scholar 

  3. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension 1993; 22: 392–403

    Article  Google Scholar 

  4. Myers MG, Carruthers SG, Leenen FHH, et al. Recommendations from the Canadian Hypertension Society Consensus Conference on the pharmacologic treatment of hypertension. Can Med Assoc J 1989; 140: 1141–6

    CAS  Google Scholar 

  5. Hypertension Guidelines Committee, South Australian Faculty, Royal Australian College of General Practitioners. Hypertension: diagnosis, treatment, and maintenance. Guidelines endorsed by the High Blood Pressure Research Council ofAustralia. Adelaide: South Australian Faculty, Royal Australian College of General Practitioners, 1991

  6. Mild hypertension: a summary of the 1993 World Health Organization/International Society of Hypertension (WHO/ISH) guidelines for the management of mild hypertension. Memorandum from a WHO/ISH meeting. J Intern Med 1994; 235:21–97

    Article  Google Scholar 

  7. Herbert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578–81

    Article  Google Scholar 

  8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64

    Article  Google Scholar 

  9. Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions of blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267: 1213–20

    Article  Google Scholar 

  10. Treatment of Mild Hypertension Research Group. The treatmentof mild hypertension study: a randomized, placebocontrolled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1992; 152: 131–6

    Article  Google Scholar 

  11. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153: 154–83

    Article  Google Scholar 

  12. Pardell H, Armario P, Hernandez R. Progress in the 1980s and new directions in the 1990s with hypertension management: from the stepped-care approach to the individualised programme in hypertension treatment and control. Drugs 1992; 43 (1): 1–5

    Article  PubMed  CAS  Google Scholar 

  13. Alderman MH. Which antihypertensive drugs first - and why? JAMA 1992; 267: 2786–7

    Article  PubMed  CAS  Google Scholar 

  14. Stason WB. Opportunities to improve the cost-effectiveness of treatment for hypertension. Hypertension 1991; 18 Suppl. 3: 1161–6

    Article  Google Scholar 

  15. Levine DM, Bone L. The impact of a planned health education approach on the control of hypertension in a high risk population. J Hum Hypertens 1990; 4: 317–21

    PubMed  CAS  Google Scholar 

  16. Balazovjech I, Hnilica Jr P. Compliance with antihypertensive treatment in consultation rooms for hypertensive patients. J Hum Hypertens 1993; 7 (6): 581–3

    PubMed  CAS  Google Scholar 

  17. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841–5

    Article  PubMed  CAS  Google Scholar 

  18. Sclar DA, Skaer TL, Chin A, et al. Utility of a transdermal delivery system for antihypertensive therapy: part II. Am J Med 1991; 91 Suppl. 1A: 57S-60S

    Article  Google Scholar 

  19. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a medicaid population. Med Care 1994; 32: 214–26

    Article  PubMed  CAS  Google Scholar 

  20. Office of National Cost Estimates. National health care expenditures, 1988 [summary]. Health Care Financ Rev 1990; 11: 125

    Google Scholar 

  21. Carney S, Gillies A, Smith A, et al. Hypertension education: patient knowledge and satisfaction. J Hum Hypertens 1993; 7 (5): 505–8

    PubMed  CAS  Google Scholar 

  22. Sharkness CM, Snow DA. The patient’s view of hypertension and compliance. Am J Prev Med 1992; 8 (3): 141–6

    PubMed  CAS  Google Scholar 

  23. Richardson MA, Simons-Morton B, Annegers JE Effect of perceived barriers on compliance with antihypertensive medication. Health Educ Q 1993; 20 (4): 489–503

    Article  PubMed  CAS  Google Scholar 

  24. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4

    Article  PubMed  CAS  Google Scholar 

  25. Farquhar JW, Fortmann SP, Flora JA, et al. Effects of communitywide education on cardiovascular disease risk factors: the Stanford five-city project. JAMA 1990; 264: 359–65

    Article  PubMed  CAS  Google Scholar 

  26. Lefebvre RC, Lasater TM, Carleton RA, et al. Theory and delivery of health programming in the community: the Pawtucket Heart Health Program. Prev Med 1987; 16: 80–95

    Article  PubMed  CAS  Google Scholar 

  27. Sawicki PT, Muhlhauser I, Didjurgeit U, et al. Improvement ofhypertension care by a structured treatment and teaching programme. J Hum Hypertens 1993; 7 (6): 571–3

    PubMed  CAS  Google Scholar 

  28. Bittar N. Maintaining long-term control of blood pressure: the role of improved compliance. Clin Cardiol 1995; 18 Suppl. 3: 312–6

    Article  Google Scholar 

  29. ScIar DA, Tessier GC, Skaer TL, et al. Effect of pharmaceutical formulation of diltiazem on medicaid and health maintenance organization services. Curr Ther Res 1994; 55 (10): 1136–49

    Article  Google Scholar 

  30. Webber GC. Patient education: a review of the issues. Med Care 1990; 28 (11): 1089–103

    Article  PubMed  CAS  Google Scholar 

  31. Skaer TL, Sclar DA, Markowski DJ, et al. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens 1993; 7 (5): 515–8

    CAS  Google Scholar 

  32. Sclar DA, Skaer TL, Chin A, et al. Effect of health education on the utilization of HMO services: a prospective trial among patients with hypertension. Prim Cardiol 1992; 18 Suppl. 1: 30–5

    Google Scholar 

  33. Vogel DP. Patient-focused care. Am J Hosp Pharm 1993; 50: 2321–9

    PubMed  CAS  Google Scholar 

  34. Lathrop JP. Patient-focused care in theory and action. Am J Health Syst Pharm 1995; 52: 45–8

    PubMed  CAS  Google Scholar 

  35. Shea S, Misra D, Enrlich MH, et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health 1992; 82: 1607–12

    Article  PubMed  CAS  Google Scholar 

  36. Francis CK. Hypertension, cardiac disease, and compliance in minority patients. Am J Med 1991; 91 Suppl.1A: 29S-36S

    Article  Google Scholar 

  37. Clark LT. Improving compliance and increasing control of blood hypertension: needs of special populations. Am Heart J 1991; 121: 664–9

    Article  PubMed  CAS  Google Scholar 

  38. Shea A, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992; 327: 776–81

    Article  PubMed  CAS  Google Scholar 

  39. Dustan HP, De Leon AC, Hill MN, et al. Report of the task force on the availability of cardiovascular drugs to the medically indigent. Circulation 1992; 85 (2): 849–60

    Article  PubMed  CAS  Google Scholar 

  40. Haywood LJ. Hypertension in minority populations: access to care. Am J Med 1990; 88 Suppl. 3B: 17S-20S

    Article  Google Scholar 

  41. Feder G. Which guidelines to follow? BMJ 1994; 308: 470–1

    Article  Google Scholar 

  42. Menard J. Oil and water? Economic advantage and biomedical progress do not mix well in a government guidelines committee. Am J Hypertens 1994; 7: 877–85

    PubMed  CAS  Google Scholar 

  43. Tobian L, Brunner HR, Cohn JN, et al. Modem strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. Am J Hypertens 1994; 7: 859–72

    PubMed  CAS  Google Scholar 

  44. Weber MA, Laragh JH. Hypertension: steps forward and steps backward. Arch Intern Med 1993; 153: 149–52

    Article  PubMed  CAS  Google Scholar 

  45. Gavras H, Gavras I. On the JNC V report: a different point of view. Am J Hypertens 1994; 7: 288–93

    PubMed  CAS  Google Scholar 

  46. Swales JD. Guidelines on guidelines. J Hypertens 1993; 11: 899–903

    Article  PubMed  CAS  Google Scholar 

  47. Swales JD. Guidelines for treating hypertension: improved care or retarded progress. Am J Hypertens 1994; 7: 873–6

    PubMed  CAS  Google Scholar 

  48. Strasser T. Relative costs of antihypertensive drug treatment. J Hum Hypertens 1992; 6: 489–94

    PubMed  CAS  Google Scholar 

  49. Menard J, Cornu P, Day M. Cost of hypertension treatment and the cost of health. J Hum Hypertens 1992; 6: 447–58

    PubMed  CAS  Google Scholar 

  50. Oparil S. Antihypertensive therapy: efficacy and quality of life [editorial]. N Engl J Med 1993; 328 (13): 959–61

    Article  PubMed  CAS  Google Scholar 

  51. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7

    Article  PubMed  CAS  Google Scholar 

  52. Winklund I. Quality of life and cost-effectiveness in the treatment of hypertension. J Clin Pharm Ther 1994; 19 (2): 81–7

    Article  Google Scholar 

  53. Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men. N Engl J Med 1993; 328 (13): 907–13

    Article  PubMed  CAS  Google Scholar 

  54. Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994; 7: 329–39

    PubMed  CAS  Google Scholar 

  55. Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med 1991; 151: 1817–23

    Article  PubMed  CAS  Google Scholar 

  56. Skaer TL. Applying pharmacoeconomic and quality-of-life measures to the formulary management process. Hosp Formul 1993; 28 (6): 577–84

    PubMed  CAS  Google Scholar 

  57. Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. PharmacoEconomics 1994; 5 (6): 482–504

    Article  PubMed  CAS  Google Scholar 

  58. Maxwell MH, Frishman WH, Kong BW. Quality-of-life considerations for first-line antihypertensive therapy. Cardiovasc Rev Rep 1994; 15: 17–22

    Google Scholar 

  59. Pool JL. Newer antihypertensive drugs: a glimpse into the future. Curr Opin Cardiol 1993; 8: 775–9

    Article  Google Scholar 

  60. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens 1992; 5 (12 Pt 2): 247S-51S

    Google Scholar 

  61. Drummond M, Coyle D. Assessing the economic value of antihypertensive medicines. J Hum Hypertens 1992; 6 (6): 495–501

    PubMed  CAS  Google Scholar 

  62. Maynard A. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6 (6): 417–20

    PubMed  CAS  Google Scholar 

  63. Kozma CM, Reeder CE, Lingle EW. Expanding medicaid drug formulary coverage: effects on utilization of related services. Med Care 1990; 28 (10): 963–77

    Article  PubMed  CAS  Google Scholar 

  64. Sclar DA, Skaer TL. Pharmaceutical formulation and healthcare expenditures. PharmacoEconomics 1992; 2 (4): 267–9

    Article  PubMed  CAS  Google Scholar 

  65. Vageloos PR. Are prescription drug prices high? Science 1991; 252: 1080–4

    Article  Google Scholar 

  66. Shulman NB, Levinson RM, Dever GE, et al. Impact of cost problems on morbidity in a hypertensive population. Am J Prev Med 1991; 7 (6): 374–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Washington State University, Pullman, Washington, 99164-6510, USA

    Tracy L. Skaer, David A. Sclar & Linda M. Robison

Authors
  1. Tracy L. Skaer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Sclar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda M. Robison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skaer, T.L., Sclar, D.A. & Robison, L.M. Noncompliance with Antihypertensive Therapy. Pharmacoeconomics 9, 1–4 (1996). https://doi.org/10.2165/00019053-199609010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199609010-00001

Search

Navigation